Evidence map›Paper›PMID 36051102›Full record

ArticleWorld journal of gastrointestinal oncology2022

Increased 5-hydroxymethylcytosine is a favorable prognostic factor of

Ying-Li Fu, Yan-Hua Wu, Dong-Hui Cao, Zhi-Fang Jia, Ao Shen, Jing Jiang, Xue-Yuan Cao

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ying-Li FuDivision of Clinical Research, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China.
Yan-Hua WuDivision of Clinical Research, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China.
Dong-Hui CaoDivision of Clinical Research, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China.
Zhi-Fang JiaDivision of Clinical Research, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China.
Ao ShenDepartment of Gastric and Colorectal Surgery, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China.
Jing JiangDivision of Clinical Research, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China.
Xue-Yuan CaoDepartment of Gastric and Colorectal Surgery, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China. jd3d2ub@jlu.edu.cn.
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMost gastric cancer (GC) patients are diagnosed at middle or late stage because the symptoms in early stage are obscure, which causes higher mortality rates of GC.

aimTo explore the association between 5-hmC levels and the progression and prognosis of GC patients with or without

methodsA retrospective cohort study was conducted to estimate the predicted value of 5-hmC level in the progression and prognosis of GC patients with different

resultsThe levels of 5-hmC were significantly decreased in tumor tissues (0.076 ± 0.048) compared with the matched control tissues (0.110 ± 0.057,

conclusionIncreased 5-hmC is a favorable prognostic factor in GC, especially for

Indexed as

5-hydroxymethylation5-hydroxymethylcytosineGastric cancerHelicobacter pyloriPrognosis

Identifiers

PMID36051102
PMCPMC9305580
OpenAlexW4284898306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.